Rilzabrutinib treatment is associated with a reduction in disease activity in patients with IgG4-related disease and enables ...

For patients presenting with moderate to severe pemphigus, the choice of initial therapy has been distilled to a single agent: rituximab. This drug is more rapidly effective, more likely to provide ...

Rituximab is associatied with numerically higher remission rates in lupus membranous nephritis, although 12-month renal response rates did not differ significantly across immunosuppressive strategies.

Although rituximab may improve central nervous system outcomes, evidence supporting its use in Sjögren disease is limited. Rituximab may improve neurologic outcomes in adults with severe or ...

Rituximab is used in the treatment of adults with several B-cell malignancies, as well as certain autoimmune conditions.

Although the anti-CD20 B-cell depleting biological agent rituximab has been shown in small series and single-arm studies to effectively treat frequently relapsing nephrotic syndrome (FRNS) and steroid ...

Please provide your email address to receive an email when new articles are posted on . The FDA has approved rituximab-arrx, in combination with methotrexate, in adult patients with moderate or ...

Fresenius Kabi, an operating company of Fresenius, announced today that the U.S. Food and Drug Administration (FDA) has approved a rituximab biosimilar developed by Dr. Reddy's Laboratories (DRL), a ...

New research presented this week at ACR Convergence, the American College of Rheumatology's annual meeting, shows immunocompromised patients using rituximab (a drug used to treat diseases like ...

The pressure is mounting on Roche after Swiss rival Sandoz filed a US biosimilar of cancer and inflammatory diseases drug rituximab, closely behind a rival from Teva and Celltrion. Rituxan (rituximab) ...

In a new study, rituximab therapy was found to be an effective treatment option for lupus nephritis (LN) management. After six months of use, people with lupus nephritis taking the therapy showed ...